Medi Labz

Rhythm notes · ECG Simulator

Atrial fibrillation

Clinical review pending: written from the sources below, not yet checked by a clinician. Updated 2026-11-22.

Wave size
Lead II · small box: 40 ms across, 0.1 mV up

In one line

The atria stop beating and quiver instead; the AV node lets through only some of the chaotic impulses, at random, so the pulse is irregularly irregular and there are no P waves.1,2

Mechanism

  • Many small waves of depolarization wander through the atria in all directions at once, so no single wave organizes a contraction.1
  • Large atria favor it. A dilated atrium gives a long pathway and slow conduction, the ideal conditions for waves to keep re-entering instead of dying out. Valve disease that stops the atria emptying, and heart failure that dams blood back into them, both stretch the atria.1
  • The AV node is the gatekeeper. After passing an impulse it cannot pass another for about 0.35 s. Then the next impulse arrives at a random moment, anywhere from 0 to about 0.6 s later. So R–R intervals vary from about 0.35 to 0.95 s, with no pattern.1
  • The atria no longer act as primer pumps. Blood still flows passively into the ventricles, so overall pumping falls by only about 20–30%, but blood can stagnate in the left atrial appendage and clot.1

Epidemiology

  • AF is the most common sustained arrhythmia, and its incidence and prevalence are rising in the United States and worldwide.2
  • An estimated 33.5 million people had AF worldwide in 2010 (Global Burden of Disease 2010).4
  • In 2021 there were about 4.48 million new cases and about 0.34 million deaths attributed to AF and atrial flutter worldwide (Global Burden of Disease 2021).5
  • Lifetime risk is high: about 1 in 4 for men and women from age 40 (Framingham).6 From age 55 it is about 1 in 5 with an optimal risk-factor profile, and more than 1 in 3 with at least one elevated risk factor.7

Causes and risk factors

  • Atrial stretch: valve lesions (especially those that obstruct atrial emptying) and heart failure.1
  • Cardiometabolic: high blood pressure (the leading attributable risk factor worldwide), then high body mass index; also diabetes.5,7
  • Lifestyle and other conditions: alcohol, obesity, smoking, sleep apnea and coronary heart disease.2,7
  • Age: incidence rises steeply with age.6

How to spot it

  1. Rate: variable. Untreated, the ventricles are often driven at about 125–150 beats/min.1 The simulator shows a controlled rate, as after rate control.
  2. Regularity: irregularly irregular. No two R–R intervals follow a pattern.1
  3. P waves: none. At most a fine, fast, low-voltage wavering baseline (fibrillatory waves).1
  4. PR interval: none, because there is no P wave to measure from.1
  5. QRS: usually narrow and normal in shape, because the ventricles are still activated through the normal His–Purkinje system.1

The diagnosis needs an ECG that captures it: the 2024 ESC guideline accepts a standard 12-lead ECG, or 30 seconds or more on a single-lead tracing.3

Differential diagnosis

  • Atrial flutter: one large wave circling the atria at about 200–350 a minute gives organized, repeating flutter waves, often with a fixed ratio such as 2:1. With variable block it can look irregular; look for the organized waves.1
  • Sinus rhythm with frequent premature beats: irregular, but each normal beat has a P wave, and the early beats stand out against an otherwise regular background.1
  • Sinus arrhythmia: irregular, but with a P before every QRS and a rate that rises and falls with breathing.1

Clinical picture

  • Symptoms range from none to palpitations, breathlessness, tiredness, dizziness or chest discomfort; some people are found only on a routine ECG or after a stroke.2,3
  • The pulse is irregularly irregular.1
  • Guidelines describe AF by its pattern over time: paroxysmal (stops on its own or with treatment within 7 days), persistent (lasts longer than 7 days), long-standing persistent (over 12 months) and permanent (patient and clinician have decided not to restore sinus rhythm).2,3

Why it matters

  • Stroke: clots that form in the left atrial appendage can travel to the brain or elsewhere. This is why stroke prevention is central to AF care.1,2
  • Heart function: losing the atrial kick costs about 20–30% of pumping efficiency, and a persistently fast rate can weaken the ventricle over time.1,2
  • Burden: AF and flutter cause hundreds of thousands of deaths a year worldwide.5

Management overview

For learning only. This is the shape of care, not a treatment plan; real decisions depend on the patient and the current guideline.

  • Unstable patient (shock, severe breathlessness, ongoing ischemia): urgent electrical cardioversion, with the shock synchronized to the QRS.1,2
  • The 2024 ESC "AF-CARE" pathway organizes the rest:3
    • C: treat comorbidities and risk factors (blood pressure, weight, alcohol, sleep apnea, diabetes, activity).2,3
    • A: avoid stroke and thromboembolism. Score stroke risk (CHA₂DS₂-VA in the 2024 ESC guideline; CHA₂DS₂-VASc in the 2023 ACC/AHA guideline) and decide on anticoagulation. Left atrial appendage occlusion is an option for some who cannot take anticoagulants.2,3
    • R: reduce symptoms with rate control (slowing AV-node conduction) and/or rhythm control (cardioversion, antiarrhythmic drugs, catheter ablation).2,3
    • E: evaluate and reassess over time, because AF and its risks change.3

Exam pearls

  • Irregularly irregular plus no P waves: think AF first.1
  • A narrow-QRS irregular rhythm with organized waves is not AF; look for flutter.1
  • AF's danger is mostly the clot, not the rhythm itself: the atria still fill the ventricles passively.1
  • Cardioversion for AF is synchronized; defibrillation for VF is not.1
  • Know both stroke scores: CHA₂DS₂-VASc (2023 ACC/AHA) and CHA₂DS₂-VA (2024 ESC).2,3

Sources

Where this comes from.

  1. Hall JE, Hall ME. Guyton and Hall Textbook of Medical Physiology, 14th ed. Elsevier; 2021. Ch. 13 (pp. 160–161, 166–167).
  2. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149(1):e1–e156. doi.org/10.1161/CIR.0000000000001193
  3. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2024;45(36):3314–3414. doi.org/10.1093/eurheartj/ehae176
  4. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837–47. doi.org/10.1161/CIRCULATIONAHA.113.005119
  5. Cheng S, He J, Han Y, et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021. Europace. 2024;26(7):euae195. doi.org/10.1093/europace/euae195
  6. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–6. doi.org/10.1161/01.CIR.0000140263.20897.42
  7. Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: Framingham Heart Study. BMJ. 2018;361:k1453. doi.org/10.1136/bmj.k1453